MolecularMatch

With the increasing numbers of new mutations being tested and resulting drugs being developed, James Welsh M.D., founded MolecularMatch in 2014, a clinical informatics company whose primary goal is to improve the utility of genomics. Licensing clinical insights from MD Anderson, MolecularMatch developed a semi-automated technology that enhances the application of precision medicine for organizations. At our core, we are a technology company and believe that expert-created knowledge and real-time information are the pillars of an “informed decision support” solution. MolecularMatch’s patent pending automated technology reads and acquires thousands of genomic data sets weekly allowing our partners to efficiently provide evidence based Recommendations. The data set includes clinical trials, targeted drug treatments, mutations, genes, automated variant classifications, scientific abstracts/publications and more all of which contributes to our knowledge platform. Through Natural Language Processing we can examine and create associations among the information faster than any human can while applying the knowledge to our proprietary algorithms. Each of our solutions are founded in this technology allowing our decision support to be one of the most scientifically driven system known. Making the power of genetic data more discoverable, understandable, accessible and useful. MolecularMatch also offers patients and physicians a complimentary search tool that matches a patient’s genetic information from their disease to an appropriate therapy. The tool creates evidence-based treatment suggestions containing: 1) FDA-approved therapies, 2) experimental drugs that are currently being tested, and 3) appropriate clinical trials. Information provided by MolecularMatch is purely for informational purposes and should not take the place of information given by a physician or healthcare provider. The tool is available as a clinical lab integration product, or for free searching at www.MolecularMatch.com.